Calcium Pyrophosphate Deposition (CPPD) Disease

NANot yet recruitingINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

November 30, 2027

Conditions
Calcium Pyrophosphate Deposition DiseaseRheumatic Diseases
Interventions
GENETIC

transcriptomic and metabolomic analysis

Venous blood samples for transcriptomic and metabolomic analysis will be taken in 3 x 4 mL ethylenediaminetetraacetic acid (EDTA) tubes and stored immediately at 4°C, before being cryopreserved at -80°C in 500 μL aliquots of plasma. In addition, for transcriptomic analysis, a sample will also be taken in a Paxgen RNA tube cryopreserved at -80°C.

Trial Locations (1)

59160

Hôpital Saint-Philibert (GHICL), Lomme

All Listed Sponsors
lead

Lille Catholic University

OTHER

NCT07005804 - Calcium Pyrophosphate Deposition (CPPD) Disease | Biotech Hunter | Biotech Hunter